The off-label treatment of relapsed / refractory (R/R) acute myeloid leukaemia (AML) following at least one line of intensive chemotherapy – this includes scenarios of molecular relapse, and relapse following allogeneic haematopoietic stem cell transplant [HSCT]) in situations where:

• it is deemed not appropriate to offer intensive ‘salvage chemotherapy’ by the treating physician / multi-disciplinary team
• the patient has not previously demonstrated refractoriness or intolerance to venetoclax-based therapy